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ngiotensin-Converting
nzyme Inhibitor Therapy
t the Time of Coronary
rtery Bypass Surgery
hen a Friend Turns Mean-Spirited*
avid S. Bach, MD
nn Arbor, Michigan
herapy with an angiotensin-converting enzyme inhibitor
ACEI) reduces cardiovascular mortality and morbidity in
atients with stable coronary artery disease (CAD) (1) and
n patients with CAD and left ventricular systolic dysfunc-
ion (2) or early after acute myocardial infarction (3). For
hese reasons, ACEI therapy has become as omnipresent
mong patients with CAD as has therapy with beta-
drenergic antagonists, statins, and aspirin. As testimony to
he weight of medical literature supporting their use, no
atient is discharged from the inpatient cardiovascular
edicine or surgical services of the University of Michigan
edical System (as is surely the case at many other
nstitutions) without documentation of having been pre-
cribed 1 of each of these medications, or a good reason why
ot. The ubiquity of their use has led some to quip that, for
urposes of public health certainly no less critical than
uoride for cavity prevention, these 4 medications should be
onsidered as additives to the public water supply.
See page 1778
By definition, patients who undergo coronary artery bypass
raft (CABG) surgery have CAD; many have systemic hyper-
ension and diabetes mellitus, and the sequelae of these
iseases including left ventricular systolic dysfunction or
hronic renal insufficiency—each an indication for ACEI
herapy. Intuition holds that this group of patients should
enefit the most from ACEI therapy. Yet, intuition has led
s astray before. Who would have predicted that the
uccessful suppression of premature ventricular beats, them-
elves a marker for adverse outcome after acute myocardial
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.b
From the Department of Internal Medicine, Division of Cardiovascular Medicine,
niversity of Michigan, Ann Arbor, Michigan.nfarction, would result in excess cardiac death (4)? If ACEI
herapy is beneficial for the diseases that bring patients to
ABG, could it be that it is actually detrimental at the time
f surgery?
he present study. In this issue of the Journal, Miceli et al.
5) report a large, retrospective, observational cohort study
nalyzing prospectively collected data from 10,000 pa-
ients undergoing CABG at a single institution in England
etween 1996 and 2008. Using propensity score matching,
subgroup of 3,052 patients receiving ACEI therapy
re-operatively was compared with a control group. The
uthors found that pre-operative ACEI therapy within 24 h
f CABG was associated with an increased risk of death,
ost-operative inotropic support, post-operative renal dys-
unction, and atrial fibrillation. The authors suggest that
uspending ACEI therapy before CABG and restarting it
ost-operatively might improve early surgical outcomes,
hile retaining the long-term cardioprotective effects of
herapy.
This study comes in the context of several others sug-
esting similar conclusions, even if the literature is not
ompletely homogeneous. As the authors note in their
iscussion, the majority of published data support the
resence of risk associated with preoperative ACEI therapy
mong patients undergoing CABG or major vascular sur-
ery. The proposed mechanism is that of perioperative
ypotension and resulting inotropic and vasoconstrictor
herapy leading to impaired renal perfusion.
tudy limitations. The present report, relying on large
atient numbers and propensity score matching, makes a
owerful statement. The authors are to be congratulated on
carefully performed and important study. However, po-
ential limitations should be recognized.
The population studied comprised patients at the Bristol
eart Institute in the United Kingdom, and might not be
epresentative of patients undergoing CABG in the U.S.
ased on available data, patients undergoing CABG in the
.S. likely have more comorbidities than those undergoing
ABG in this study (6). But if underlying risk factors
redispose patients to adverse outcomes independent of, or
ynergistically with, the use of ACEI therapy, differences in
utcomes might even be amplified in the U.S. However,
his study reports perioperative mortality and morbidity
ates that appear higher than anticipated for the patients
escribed and, unlike the U.S. population (6), no decrease in
perative risk over the 13 years of the study. Taking the case
f a 65-year-old man (body surface area 1.95 m2) with
ypertension, moderate chronic lung disease, remote myo-
ardial infarction, ejection fraction 54%, and creatinine 1.3
g/dl (110 mol/l) undergoing isolated first-time 3-vessel
ABG—approximating the average patient in this study—
he Society of Thoracic Surgery risk calculator estimates
.7% perioperative mortality (7), substantially lower than
he 1.0% observed. On the basis of current practice, it could
e assumed that most patients undergoing CABG in the
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ACEI Therapy November 3, 2009:1785–6.S. are treated with an ACEI. If it is true that perioper-
tive mortality in the U.S. is lower despite a sicker popula-
ion, then it remains unknown whether the risks associated
ith ACEI therapy apply here, as well.
If the mechanism of death and post-operative renal
ysfunction associated with ACEI therapy is mediated by
erioperative hypotension and requirement for inotropic
upport, then 1) why was ACEI therapy barely among the
ndependent predictors of requirement for postoperative
notropic support (ranking 8 of 10 factors); and 2) why is
isk related specifically to ACEI therapy and not to treat-
ent with any antihypertensive agent?
The latter question begs at least a comment regarding
ropensity score matching. As a sophisticated tool to reduce
ias caused by observed differences between groups in an
bservational study (by balancing covariates across groups)
8), the temptation is to treat the subjects as if they had been
andomly assigned. However, propensity score matching
an only account for factors that were measured, and only as
ell as they were measured. If antihypertensive therapy in
eneral was not a risk for perioperative inotropic support or
ther end points, then ACEI therapy must be different. But
s ACEI therapy an intrinsic risk factor, or is it a marker for
omething else—perhaps for more severe hypertension? Or
erhaps even for hypertension that was better controlled?
ow dogmatic is dogmatic enough? For patients with
AD, ACEI therapy is good. Therapy with a beta-blocker
s good. Therapy with a statin is good. And we love aspirin,
oo. But is it necessary, or even advisable, that every
edication is used simultaneously and maintained indefi-
itely for all patients who carry the diagnosis? Are we
ecessarily helping patients by inducing hypotension and
enal insufficiency in the setting of an acute myocardial
nfarction? Yet, we risk censure if we do not.
To put some data in perspective, the EUROPA (EURopean
rial On reduction of cardiac events with perindopril in
table coronary Artery disease) study found that 50 patients
ould need to be treated for 4 years to prevent 1 major
ardiac adverse event (1). And the ACE Inhibitor Myocar-
ial Infarction Collaborative Group found that only 5 lives
ould be saved per 1,000 patients treated with ACEI
herapy, and that therapy was associated with a 2-fold
ncidence of both persistent hypotension and renal dysfunc-
ion (3). aIt may not be in every patient’s best interest to be treated
ith every pharmacologic agent that has been shown, on
verage, to be associated with an improved outcome, be-
ause our patients are not averages. While we await pro-
pective randomized data from patients who most resemble
hose we routinely treat, the study by Miceli et al. (5) should
rovide pause. Even if there is a net benefit over the long
erm, there may be short-term risk associated with some
harmacotherapies. Being dogmatic in our use of these
gents should be balanced by a modicum of caution and a
illingness to keep our eyes open for possible short-term
and avoidable) risks that they may pose.
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